Atherosclerotic peripheral artery disease affects 8% to 12% of Americans >65 years of age and is associated with a major decline in functional status, increased myocardial infarction and stroke rates, and increased risk of ischemic amputation. Current treatment strategies for claudication have limitations. PACE (Patients With Intermittent Claudication Injected With ALDH Bright Cells) is a National Heart, Lung, and Blood Institute-sponsored, randomized, double-blind, placebo-controlled, phase 2 exploratory clinical trial designed to assess the safety and efficacy of autologous bone marrow-derived aldehyde dehydrogenase bright (ALDHbr) cells in patients with peripheral artery disease and to explore associated claudication physiological mechanisms.
A therosclerotic lower-extremity peripheral artery disease (PAD) affects at least 4.5% of adults >40 years of age and as many as 8% to 12% of Americans >65 years of age. [1] [2] [3] PAD is associated with a major decline in functional status, increased myocardial infarction and stroke rates, and increased risk of critical limb ischemia and ischemic amputation. [4] [5] [6] Claudication represents the most prevalent limb ischemic symptom, affecting 1 to 3 million Americans, with a similar impact on individuals with PAD worldwide. 6 Claudication is associated with proximal arterial stenoses and occlusions, limitations in arteriolar vasodilatory capacity, progressive muscle fiber denervation, skeletal muscular mitochondrial metabolic abnormalities, local inflammation, and myofibril atrophy. 7 The relationship between large-artery blood flow and claudication severity, as most commonly assessed in practice, is not strong because large-artery pressure measurements (eg, the ankle-brachial index [ABI]) are not well correlated with peak exercise performance. 7 Thus, the pathogenesis of claudication symptoms is complex and incompletely understood. Current claudication therapies are associated with significant limitations. Claudication pharmacotherapy (eg, cilostazol) may not achieve an ideal response rate, and supervised exercise efficacy may be limited by comorbidities. Furthermore, primary endovascular or open surgical revascularization may not be feasible, durable, or cost-effective. 8 Cell therapy may represent a promising approach to address the functional limitations in claudication. Bone marrow-derived stem cells may provide multiple potentially beneficial paracrine effects, for example, by directly stimulating angiogenesis or arteriogenesis. Preclinical data demonstrated increased blood flow after delivery of bone marrow-derived aldehyde dehydrogenase bright (ALDHbr) cells in severely ischemic limbs. 9 These cells, characterized by the expression of high levels of the cytosolic enzyme aldehyde dehydrogenase, contain potent stem and progenitor cells capable of ischemic repair and include hematopoietic, endothelial, and mesenchymal cell types.
The vast majority of cell therapy trials in PAD have used autologous bone marrow-derived mononuclear cells and focused on critical limb ischemia. [10] [11] [12] [13] There have been a total of 10 randomized controlled trials in patients with critical limb ischemia 14 that evaluated bone marrow-derived cells. To date, only 1 randomized controlled clinical trial has evaluated the potential of these cells to improve exercise performance in claudication. 15 Given the paucity of cell therapy trials in patients with claudication and the positive preclinical work in ALDHbr cells, the Cardiovascular Cell Therapy Research Network (CCTRN) noted the need for a clinical trial with both clinical and physiologically focused end points.
The National Heart, Lung, and Blood Institute-sponsored PACE study (Patients With Intermittent Claudication With ALDH Bright Cells) was designed to evaluate a set of anatomic and physiological effects hypothesized to underlie the potential efficacy of the proposed therapeutic approach. Both traditional exercise performance outcomes and novel magnetic resonance imaging (MRI) measurements were implemented to identify key links among PAD anatomy, function, and symptoms and to provide data that would inform future investigational efforts to improve the assessment and treatment of claudication.
METHODS
PACE was a phase II randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of administration of ALDHbr cells versus cell-free placebo in individuals with PAD and intermittent claudication (ClinicalTrials.gov identifier NCT01774097) on clinical and MRI-based measures of perfusion. It is important to note that PACE was not designed to serve as a pivotal PAD cell therapy outcomes trial because
Clinical Perspective
What Is New?
• Administration of aldehyde dehydrogenase bright cells by direct injection into the lower thigh and calf muscles was safe and feasible.
• Assessment of magnetic resonance imagingderived vascular outcomes can be performed in a multicenter study context to define potential determinants of claudication severity.
• Patients with intermittent claudication who received aldehyde dehydrogenase bright cells did not demonstrate an increase in peak walking time or improvement in magnetic resonance imaging-derived collateral count or perfusion outcomes.
What Are the Clinical Implications?
• Leg conduit artery anatomy, collateral count, peak hyperemic popliteal flow, and capillary perfusion may be systematically evaluated in future peripheral artery disease clinical trials by magnetic resonance imaging to assess how these factors contribute to claudication severity and functional capacity.
• The data to date suggest that claudication functional status, as defined by peak walking time, is not directly correlated to magnetic resonance imaging-based peripheral artery disease perfusion measurements. • Higher aldehyde dehydrogenase bright doses, repeated delivery, or alternative delivery methods applied in future studies designed in alignment with exploratory mechanistic insights may yet inform achievement of a clinically useful treatment effect in patients with symptomatic peripheral artery disease.
the cell type, dosage, timing of dosing, local physiological mechanisms, and treatment effect of potential cell types are unknown. Rather, PACE was designed as a phase II investigation that would provide unbiased treatment effects for each of the 4 primary end points and evaluate a wide set of pre hocdefined physiological relationships that could inform PAD claudication research. These secondary exploratory goals were equal in importance to the evaluation of any primary clinical end point. The detailed rationale and design of this study and its diverse objectives have been published. 16 PACE tested 4 hypotheses concerning the effects of ALDHbr cell administration in participants with PAD and intermittent claudication by evaluating changes from baseline to 6 months in the following: peak walking time (PWT), number of collateral arteries (collateral count) in the treated limb, MRI-measured popliteal artery peak hyperemic flow, and MRI measurement of limb perfusion. The protocol also specified an evaluation of the relationships between MRI measures of capillary count, large-artery (popliteal) flow, and capillary perfusion and clinically relevant measurements of limb function evaluated with traditional exercise testing methods. The protocol was approved by local institutional review boards at each of the 9 participating sites. All participants provided written informed consent before participation.
Patients ≥40 years of age with a diagnosis of atherosclerotic lower-extremity PAD with symptom-limiting intermittent claudication were recruited. Because the protocol stipulated that only 1 leg be treated, it was necessary for participants to exhibit claudication symptoms that were greater in 1 leg (the index leg), with documentation of no aorto-iliac (inflow) stenosis and with a significant (≥50%) stenosis or occlusion of at least 1 infrainguinal arterial segment (eg, the superficial femoral, popliteal, or infrapopliteal artery). Patients with prior index leg bypass grafts were included in PACE only when the bypass graft was occluded. Thus, all stenoses were in the native artery.
Baseline evaluations were conducted over a 60-day screening period to determine eligibility. Claudication severity and patient-reported health status and quality of life were evaluated by the San Diego Claudication Questionnaire, 17 Walking Impairment Questionnaire, 18 and Peripheral Arterial Questionnaire. 19 Baseline ABI and Gardner-Skinner exercise treadmill testing were performed to document the index leg claudication limitation of 12 minutes, a period of exercise that would distinguish changes related to cell administration. MRI angiography was performed to document PAD anatomy and to conduct resting and postocclusion reactive hyperemia testing.
Eligible participants were randomized 1:1 to receive either ALDHbr cells or cell-free placebo that was delivered under blinded protocol-specified conditions.
ALDHbr Cell Production
ALDHbr cells were sorted from fresh bone marrow without prior stimulation, postprocessing, or culture. Approximately 180 mL (±10 mL) of bone marrow was aspirated from the iliac crests from both cell and placebo group participants. To isolate ALDHbr cells for cell group participants, the marrow was shipped via courier service to 1 of 2 cell-processing facilities. Ten patients had cells processed at Aldagen facilities (Durham, NC), and 27 patients had cells processed at the Baylor Center for Cell and Gene Therapy (Houston, TX). The product was prepared by enriching mononuclear cells from the marrow with a Sepax device (Biosafe, Geneva, Switzerland), staining the primitive stem cells for the intracellular enzyme ALDH, and aseptically sorting with a fluorescence-activated Aria cell sorter (Becton Dickenson, San Jose, CA). The product was returned by courier service to the clinical center for administration within 96 hours of marrow aspiration. The placebo product consisted of phenol red-free CellGro SCGM serum-free medium (CellGenix Technologie Transfer GmbH, Frieburg, Germany) supplemented with 1% human serum albumin (Flexbumin, Baxter, IL). Both study products (cells and placebo) were identical in appearance.
Study Product Delivery
The objective of delivery was the placement of study product at the depth of the muscular mass of the calf (gastrocnemius) and lower thigh (semimembranosus and biceps femoris). The index leg was confirmed; skin was anesthetized with a topical lidocaine cream; and injection sites were marked with a standardized template for the ten 1-mL injections.
Follow-Up Evaluations
Randomized participants were followed up for safety and efficacy for 6 months (180±30 days), with evaluations on the day of injection, at 1 week, and at 1, 3, and 6 months. Quality-of-life measures and telephone communications with the participants were described in the PACE design article. 16 Treadmill and ABI or toe-brachial index testing was conducted at 3 and 6 months. MRI measurements were performed at 6 months for the primary end-point assessment. Participants were considered lost to follow-up after 3 consecutive failed telephone contacts and 1 undeliverable certified letter.
Safety Monitoring
All study participants were closely monitored for adverse events; safety data were transmitted to the institutional review boards of each center, the Data Coordinating Center, the US Food and Drug Administration, and the National Institutes of Health (NIH)-sponsored Data and Safety Monitoring Board as required by the protocol.
Biorepository
All participants who consented to sample donations had bone marrow aspirate and peripheral blood shipped to the CCTRN Biorepository Core Laboratory (Texas Heart Institute, Houston, TX) for phenotyping and functional analyses. 20 
MRI Study
The PACE MRI Core Laboratory (Johns Hopkins University, Baltimore, MD) assisted with end-point selection, trained and monitored sites on MRI procedures, and performed MRI sitespecific quality and outcome assessments. 21 Bulk macrovascular blood flow to the calf muscle was assessed with a phase-contrast MRI sequence in conjunction with cardiac gating. Peak arterial blood flow and the time-resolved flow curve across the RR interval were measured for the vessel of interest. Arterial flow reserve was calculated from the ratio of flow measured at resting and hyperemic states. Reactive hyperemia was induced in the index leg with release of inflatable cuff occlusion.
Treadmill Testing
The Treadmill Core Laboratory (Colorado Prevention Center, Aurora) trained and monitored treadmill testing, ABI/toe-brachial index measurement, and quality-of-life survey administration at each site. Participants had 2 treadmill tests at baseline that used a graded Gardner-Skinner protocol 22 with ECG monitoring. The maximum PWT of these 2 tests was used for baseline.
Statistical Analysis
The sample size calculation, based on the CLEVER trial (Claudication: Exercise Versus Endoluminal Revascularization), estimated that 78 participants would be required to detect a 2.5-minute difference in the increase in PWT from baseline to 6 months in ALDHbr-treated participants compared with the change in placebo-treated participants, assuming a standard deviation of the difference over time of 3 minutes, 90% power, and 15% loss to follow-up. 23 At this sample size, the power for the change in collateral count, peak hyperemic popliteal flow, and capillary perfusion, each with 2-tailed t tests, was >90%. 24, 25 The statistical analysis plan has been reported. 16 Fisher exact tests for categorical variables and Student t tests for continuous variables assessed the between-group compatibility of baseline variables. Within-group results are reported as mean±SD. Between-group results are reported as mean±SEM. Primary outcome differences were considered significant at the <0.05 level. All primary analyses were conducted with the intention-to-treat principle. However, because a small number of participants neither received therapy nor had follow-up data to permit an analysis, a modified intention-to-treat analysis was conducted in participants who received study product.
To compare the effect sizes obtained in PACE and CLEVER, a standardized effect unit (SEU) was computed for PWT. The SEU is the observed effect size divided by the standard deviation of the placebo group.
The study investigational product effect on the difference between change in these 4 outcomes over time in the 2 groups was assessed with a general linear model that included baseline covariates that were significantly different across treatment groups. In addition, nonparametric Wilcoxon 2-sample tests were applied in a sensitivity analysis. There were no corrections for multiple comparisons of the 4 coprimary end points per the original statistical analysis plan. Weight-adjusted P values also were computed because of body weight differences between the ALDHbr and placebo cohorts.
Because the exercise data were assessed at baseline, 3 months, and 6 months, a general linear model with explainer variables including time, treatment assignment, and time-treatment interaction was conducted. The P values reported are for the time-treatment interaction.
Subgroup analyses assessing the relationship between study product delivery and the primary and secondary end points were performed. Prespecified subgroups included age (above versus below median), sex, race, baseline preexercise ABI, diabetes mellitus, hypertension, low-density lipoprotein cholesterol and statin use, smoking status, and body mass index. As described in the PACE design article, a diverse set of exploratory analyses were declared a priori to define the relationships between the effects of cell therapy on MRI measures of limb anatomy, flow, and perfusion in PAD clinical subgroups.
RESULTS
PACE evaluated potential study participants from June 2013 to December 2015; 1902 individuals were identified who were ≥40 years old with PAD and intermittent claudication or atypical leg pain (Figure) . This total represents the larger PAD clinic population and does not represent individuals meeting the entry criteria. Of these individuals, 122 individuals met the entry criteria, provided consent for trial participation, and underwent baseline evaluations, resulting in 82 participants who met the eligibility criteria and underwent treatment randomization.
From this randomized cohort, 4 participants did not receive study product. One failed to appear for the bone marrow aspiration. Two participants withdrew because of adverse events, 1 with a new prostate cancer diagnosis established before any PACE study procedures and 1 because of moderate nausea and vomiting after aspiration. The fourth participant's product experienced a cell-processing failure, and that individual subsequently withdrew consent from study participation. None of these 4 participants had primary end-point measurement at 6 months and were excluded from end-point analyses.
Treated participants had a mean age of 66±9 years. Women constituted 27% of participants; 13% were nonwhite, and 9% were Hispanic (Table 1) . Approximately 45% of participants had undergone a prior PAD endovascular procedure. The baseline pre-exercise ABI in the index leg was comparable between the ALDHbr and placebo cohorts (ABI, 0.60±0.14 and 0.63±0.11, respectively; P=0.646). Despite randomization, ALDHbr-treated participants had a lower body weight than placebo participants (167±40 versus 193±43 lb, respectively; P=0.007), with a comparable imbalance in the body mass index between the 2 groups (26.4±5.8 versus 29.3±5.0 kg/m2; P=0.022).
The treated study cohort included 38 participants in the ALDHbr group and 40 participants in the placebo group. To preserve the blind, 1 participant received placebo rather than the allocated ALDHbr assignment because of a scheduling problem but was included in the cell group per the intention-to-treat analysis plan. The number of participants in each cohort who completed each primary outcome assessment was slightly less than the randomized total and is noted in the CONSORT(Consolidated Standards of Reporting Trials) diagram (Figure) .
ALDHbr Characteristics
All cell preparations given to the participants met release criteria for sterility ( 
Primary End Points

PWT Primary Outcome Measurement
The PWT increased by 2.2±3.9 minutes (P=0.001) in the ALDHbr participants from baseline to 6 months. The placebo cohort also experienced an increase in the PWT (1.2±2.7 minutes; P=0.004). However, the mean difference in the change between the 2 cohorts was not significant (0.9±0. Table 3 ).
MRI Primary Outcome Measurements
There were 3 MRI coprimary end points in PACE. Collateral count, defined as the total number of collateral arteries (thigh and calf) observed, increased by 1.5±2.7 arteries (P=0.001) in the ALDHbr group and by 0.6±2.2 arteries in the placebo group (P=0.090) compared with baseline. The mean difference in the change over time in the number of collaterals between these 2 groups was not statistically significant (0.9±0.6 arteries; 95% CI, −0. Table 3 ).
There also was no change in the capillary perfusion measurements at 6 months compared with baseline for either the ALDHbr group (−0.42±2.40%; P=0.281) or the placebo group (−0.25±2.36%; P=0.514). The difference in the change in perfusion between the ALDHbr and placebo participants was not statistically significant (−0.17±0.55%; 95% CI, − 
Secondary End Points
Relationships Between PWT and MRI Measures
There were no significant correlations between baseline or change in PWT and baseline or change in MRI measures (Figures I and II in the online-only Data Supplement).
Exercise Data
Secondary analyses include an evaluation of the change in exercise variables measured at baseline, 3 months, and 6 months to assess the effect of ALDHbr cells on the temporal rate of change (slope) for these variables. tion, there was no significant difference in PWT between baseline and 3 months (P=0.158), nor were there differences between secondary MRI end points from baseline to 6 months between the 2 treatment cohorts.
Quality-of-Life Measurements
The effect of ALDHbr cells on Peripheral Arterial Questionnaire and Walking Impairment Questionnaire outcomes was examined with a weight-adjusted analysis. There were no differences in the change in Peripheral Arterial Questionnaire measurements from baseline to 6 months between ALDHbr cells and placebo participants for any of the survey domains: physical limitation (mean difference, 1.5±1.9; 95% CI, −2.1 to 5.1; P=0.418), symptoms (mean difference, 0.8±1.7; 95% CI, −2.5 Pre-Exercise ABI There were no significant changes in the posttreatment pre-exercise ABI values for either group. The ALDHbr group had a baseline pre-exercise ABI of 0.60±0.14 and ABIs of 0.62±0.14 and 0.61±0.17 at 3 and 6 months after treatment. The placebo group had a baseline preexercise ABI of 0.63±0.11 and ABIs of 0.62±0.14 and 0.64±0.14 at 3 and 6 months after treatment.
Subgroup Analyses
There were no statistically significant effects of cell therapy for the prespecified subgroups of age, sex, race, diabetes mellitus, hypertension, or statin use. There were too few participants using cilostazol at baseline to assess this relationship.
A prespecified subgroup analysis was also performed on the basis of patients with a low (<0.60) baseline preexercise ABI. There were 28 participants who had a base- line resting ABI ≤ 0.60 in the index leg. In the 14 ALDHbr participants, the mean collateral count increased from baseline to 6 months by 2.4±3.0 (P=0.004). In the placebo group, the increase was only 0.5±1.7 (P=0.257).
The difference in the change between the 2 groups was statistically significant (1.9±0.9; 95% CI, −0. Table 4 ). The effect of therapy on the other 3 coprimary end points in this subgroup strata was not statistically significant, nor was the effect of the therapy in the subgroup of patients whose ABI was >0.60 (P for interaction=0.197). For subgroup analyses in which subgroup membership is based on a threshold value, it is possible that these findings are due to a regression to the mean phenomenon.
Safety
Between onset of study procedures and the 6-month follow-up visit, 1 serious adverse event (limb ischemia requiring revascularization) occurred in the ALDHbr group. There were 5 serious adverse events in 5 participants in the placebo group, including a diagnosis of bladder cancer, limb ischemia requiring revascularization, a coronary artery bypass graft procedure, 1 percutaneous intervention, and 1 hospitalization for anemia. All reported events were deemed unrelated to therapy or were expected events, and none met protocol-specified requirements for reporting to the US Food and Drug Administration. There were no deaths during the 6-month follow-up period.
Hypothesis-Generating Post Hoc Analysis of Interest
The mechanistic evaluation of large-artery flow (resting flow, peak hyperemic popliteal flow, and flow reserve), arteriogenesis (collateral count), and angiogenesis (capillary perfusion) permitted an opportunity for additional pre hoc-defined analyses that were not designed to serve as pivotal outcomes. 26 Instead, these weight-adjusted analyses and relationships performed within a trial of limited sample size were intended to provide data that might underpin future hypothesis-based PAD cell therapy investigation.
At baseline, 54 participants (ALDHbr cell and placebo combined) with occluded femoral arteries on MRI at baseline and 6-month had higher collateral counts (5.1±4.4) compared with 21 participants with patent femoral arteries (2.9±3.1; P=0.015). In these 54 participants with occluded femoral arteries, ALDHbr cell delivery compared with placebo was associated with a significant mean increase in collateral count over time (1.5±0.7; 95% CI, 0.1-2.9; P=0.047; Table 4 ). This outcome, although potentially informative for future trials, is limited by the clinical heterogeneity of the population and the overall negative results on the 4 coprimary end points.
DISCUSSION
This multicenter clinical study was designed to use precise MRI anatomic and physiological measurements to evaluate the feasibility of treating patients with PAD with moderate claudication using autologous, bone marrow-derived ALDHbr cells. Efficacy measures evaluated relationships between limb blood flow (large artery and capillary) and claudication symptoms. Our results demonstrate study feasibility, defined as the successful recruitment and evaluation of qualifying participants with sophisticated magnetic resonance anatomic and physiological outcomes in a multicenter PAD clinical trial setting. In addition, we detected no adverse safety signals. However, the findings of PACE also highlight the complexity of the pathophysiology of claudication at a level of detail not previously possible.
PACE Primary Outcomes
We did not observe significant changes for any of the 4 primary efficacy end points in response to the administration of ALDHbr cells. Primary end-point variability estimates aligned with PACE design phase assumptions and suggest that the absence of a significant treatment effect was not due to measurement variability.
The hypothesis that PWT might increase after treatment with autologous bone marrow-derived ALDHbr cells may, however, deserve further consideration. In the entire cohort, the placebo-adjusted effect of ALDHbr cells on PWT was almost a 1-minute difference between groups in individuals with a baseline 5-minute PWT, yielding an ≈20% net increase in this functional status outcome. However, this effect was not statistically significant, and its 95% CI of −0.6 to 2.5 minutes is consistent with a smaller increase in PWT than placebo. However, in prior drug trials of medications such as propionyl-lcarnitine, a similar increase was noted that became statistically significant in a meta-analysis. 27 Improvements in PWT of 25% by pharmacological agents have also been associated with better patient-reported outcomes. 28 Thus, the change in PWT in PACE, if confirmed in a future appropriately powered clinical trial, may be of potential clinical importance. In addition, the 1-minute difference observed between the ALDHbr and placebo groups in PACE (SEU=0.34) may be interpreted as representing more than half of the well-defined "stent revascularization treatment effect" of CLEVER (SEU=0.58).
Claudication Physiology in PACE
In most PAD clinical trials, only the ABI has been available to assess differential treatment effects on limb hemodynamics. The PACE study data provide a more reliable evaluation of the relationship between flow and perfusion in humans with PAD by the assessment of resting and peak hyperemic popliteal flow, both at baseline and in response to delivery of either ALDHbr cells or placebo. These data demonstrate that these measurements do not correlate with symptom outcomes in well-characterized individuals with PAD. The observation that large-artery flow does not predict limb function 7 (or symptoms) was first demonstrated by Hiatt et al 29 in 1988 . Similarly, the clinical benefits of cilostazol and supervised exercise are not directly related to changes in large-artery blood flow. 7 The Utility of Novel MRI PAD Anatomy and Perfusion Measurements Many claudication therapies have been hypothesized to improve leg ischemia via direct or indirect effects on muscle perfusion. For example, cilostazol has been proposed to elicit its beneficial effects by increasing cAMP and nitric oxide generation and thereby redistribute blood toward working limb skeletal muscle. 30 Supervised exercise improves claudication via diverse mechanisms that include arteriolar dilation without directly improving limb blood flow. 31 Thus, mechanistic knowledge gaps suggested the potential utility of MRI to noninvasively quantify physiological effects of current or new claudication treatments, including cell administration.
In PACE, MRI was used to define study baseline and posttreatment collateral count, peak hyperemic popliteal flow, and capillary perfusion at baseline and 6 months after treatment. We anticipated that this anatomic and physiological evaluation of a novel cell-based intervention in vivo would enable direct determination of potential angiogenic effects of these cells in an ischemic lower limb. Despite low magnetic resonance outcome variability, both at rest and after reactive hyperemia, these data indicate that the physiological relationships of these measures to clinical symptoms are complex. 16 Furthermore, our results support the conclusion that these anatomic and perfusion factors are not strongly associated with the limiting symptoms experienced by PAD patients.
The observation of a possible differential effect of cell administration dependent on the severity of PAD occlusive disease is intriguing and might suggest a nonvascular (metabolic or endothelial) mechanism of action in the context of clinical benefit. These mechanisms might be evaluated by additional novel techniques (eg, MRI oximetry, metabolomics, or near-infrared spectroscopy evaluation of muscle hemoglobin saturation during the dynamic transition from rest to exercise).
ALDHbr Cell Administration Safety
Because PAD and claudication are prevalent, the safety of new claudication treatments should always be demonstrated in proof-of-concept clinical research trials. In PACE, there were no major adverse sequelae from the harvesting of autologous bone marrow. Bone marrow harvesting is used routinely and with demonstrated safety in the outpatient setting for the treatment of hematologic and other disorders. 32 The cellprocessing methodology was effective in creating the ALDHbr-enriched study product, with proven sterility and stable biological characteristics. Last, administration of ALDHbr cells in PACE was not associated with significant limb or systemic adverse effects. This safety profile is consistent with that observed when ALDHbr cells were administered to participants with critical limb ischemia 33 and in a small study of subjects with heart failure. 34 
Conclusions
ALDHbr cell administration did not change PWT, MRI anatomic, or MRI perfusion outcomes. In addition, the resting PWT and change in PWT were not associated with collateral count, peak hyperemic popliteal flow, or capillary perfusion, suggesting that other physiological mechanisms contribute to claudication limitations. The MRI techniques developed for this study may be used in future PAD clinical research to identify the ideal cell dose and timing of ≥1 cell administrations and thereby to determine whether a clinically relevant therapeutic benefit might be achieved.
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